Does Zepbound Cause Low Libido? Sexual Side Effects Explained

Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management that works by activating GIP and GLP-1 receptors to reduce appetite and promote significant weight loss. As with any new medication, patients may wonder about potential side effects, including whether Zepbound causes low libido or sexual dysfunction. While gastrointestinal symptoms are the most commonly reported adverse effects, questions about sexual health remain important for individuals considering or currently using this treatment. Understanding the relationship between weight loss medications and sexual function can help patients make informed decisions and recognize when to seek medical guidance.

We offer compounded medications and Zepbound®. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. References to Wegovy®, Ozempic®, Rybelsus®, Mounjaro®, or Saxenda®, or other GLP-1 brands, are informational only. Compounded and FDA-approved medications are not interchangeable.

What Is Zepbound and How Does It Work?

Zepbound (tirzepatide) is a prescription medication approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. It is manufactured by Eli Lilly and is the first FDA-approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.

By activating these receptors, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, and slows gastric emptying. These effects collectively reduce appetite and caloric intake, leading to significant weight loss.

Zepbound is administered as a once-weekly subcutaneous injection, with a recommended titration schedule starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until the target dose (maximum 15 mg) is reached. This gradual titration helps minimize gastrointestinal side effects. In clinical trials (SURMOUNT-1), participants lost approximately 15-20% of their body weight over 72 weeks, with results varying by dose.

The medication is indicated for use alongside a reduced-calorie diet and increased physical activity. It is not approved for type 2 diabetes management, though the same active ingredient is marketed as Mounjaro for diabetes treatment. Zepbound should not be used with other GLP-1 receptor agonists or weight loss products unless directed by a healthcare provider.

Important safety information includes a boxed warning for thyroid C-cell tumors and contraindication in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Other warnings include risk of pancreatitis, gallbladder disease, acute kidney injury, and it is not recommended in patients with severe gastrointestinal disease. Zepbound is not recommended during pregnancy and should be discontinued at least one month before planned conception.

Does Zepbound Cause Low Libido or Sexual Side Effects?

Based on current FDA-approved prescribing information and clinical trial data, there is no established direct link between Zepbound and low libido or sexual dysfunction. Sexual side effects, including decreased libido, are not listed among the common or serious adverse reactions in the official product labeling. The most frequently reported side effects in clinical trials were gastrointestinal in nature, including nausea, diarrhea, vomiting, constipation, and abdominal pain.

However, the absence of sexual dysfunction in formal adverse event reporting does not definitively rule out the possibility of individual experiences. Post-marketing surveillance and real-world use may reveal side effects not captured in controlled clinical trials, which typically have specific inclusion criteria and limited follow-up periods. Patients should be aware that any new medication can potentially affect individuals differently.

It is important to distinguish between direct pharmacological effects and indirect consequences of treatment. While there is limited evidence for direct hormonal effects of Zepbound on sexual function, the medication's effects on the body—including significant weight loss, changes in eating patterns, and gastrointestinal symptoms—may indirectly influence sexual function and desire. Interestingly, weight loss (including with GLP-1 receptor agonists) has been shown to improve sexual function in some populations, particularly by addressing underlying metabolic factors.

Patients experiencing changes in sexual function while taking Zepbound should not assume the medication is the cause without proper medical evaluation. Multiple factors may contribute to libido changes, and a thorough assessment by a healthcare provider is essential to identify the underlying cause and determine appropriate management strategies. Patients should seek urgent medical attention for severe abdominal pain (possible pancreatitis) or new/worsening depression or suicidal thoughts. Suspected adverse effects can be reported to the FDA MedWatch program.

Why Weight Loss Medications May Affect Sexual Function

While Zepbound does not have a documented direct effect on libido, understanding the complex relationship between weight loss medications and sexual function is important for patients and clinicians. Several indirect mechanisms may influence sexual desire and performance during weight loss treatment, regardless of the specific medication used.

Extreme caloric restriction and rapid weight loss can affect hormone levels, though the effects differ by sex. In men, moderate weight loss typically increases testosterone levels, which may improve sexual function. In women, significant weight loss may affect menstrual cycles and ovulation, potentially improving conditions like polycystic ovary syndrome (PCOS) but also potentially increasing fertility and pregnancy risk. Severe energy deficits, rather than typical supervised pharmacologic weight loss, are more likely to suppress the hypothalamic-pituitary-gonadal axis.

Gastrointestinal side effects, which are common with GLP-1 and GIP receptor agonists like Zepbound, may indirectly affect sexual function by causing discomfort, fatigue, or reduced overall well-being. Nausea, bloating, and digestive disturbances can diminish interest in sexual activity and reduce quality of life during the initial treatment period. Most gastrointestinal symptoms improve over time as the body adjusts to the medication.

Psychological factors also play a significant role. Body image changes during weight loss can affect sexual confidence both positively and negatively. Some individuals experience improved self-esteem and increased libido as they lose weight, while others may struggle with loose skin, changing body proportions, or relationship dynamics. Pre-existing mental health conditions, including depression and anxiety—which are more prevalent in individuals with obesity—can independently affect sexual function and may be exacerbated or improved during weight loss treatment.

Women using oral contraceptives should be aware that Zepbound may reduce the effectiveness of these medications. Backup contraception is advised for 4 weeks after starting Zepbound and after each dose increase.

What to Do If You Experience Libido Changes on Zepbound

If you notice changes in sexual desire or function after starting Zepbound, it is important to approach the situation systematically and communicate openly with your healthcare provider. Do not discontinue the medication without medical guidance, as abrupt cessation may affect your weight management goals and overall treatment plan.

First, document the timeline and nature of your symptoms. Note when the changes began relative to starting Zepbound or dose adjustments, the severity of symptoms, and any other concurrent changes in your health, medications, or life circumstances. This information will help your provider determine whether the medication is likely contributing to your symptoms or if other factors are involved.

Schedule a comprehensive evaluation with your healthcare provider to discuss your concerns. Your provider should assess for alternative explanations with targeted testing, which may include:

• Hormonal evaluation: For men, morning total testosterone; for women, thyroid function, prolactin levels if indicated, and pregnancy testing if menstrual changes occur

• Cardiovascular assessment: For men with erectile dysfunction, blood pressure, lipid panel, and diabetes screening as ED can be an early marker of cardiovascular disease

• Medication review: Evaluation of all medications for potential interactions or side effects

• Mental health screening: Assessment for depression, anxiety, or relationship issues

Your provider may recommend several management strategies depending on the findings. These may include dose adjustment of Zepbound, nutritional optimization, treatment of any identified hormonal imbalances, or referral to specialists such as endocrinologists, urologists, gynecologists, or certified sex therapists. In some cases, temporary supportive measures or lifestyle modifications may be sufficient to address the issue while continuing weight loss treatment.

If you are using oral contraceptives, use backup contraception for 4 weeks after starting Zepbound and after each dose increase. If pregnancy occurs, discontinue Zepbound immediately. If planning pregnancy, stop Zepbound at least one month before attempting conception.

Seek immediate medical attention for warning signs such as severe abdominal pain (possible pancreatitis) or new/worsening depression or suicidal thoughts. Consider reporting any suspected adverse effects to the FDA MedWatch program to help improve medication safety monitoring.

Frequently Asked Questions